fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Estradiol

All products: general benefit

Lupin-Estradiol · DIN 02449064 · 2 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Lupin-Estradiol · DIN 02449064 Manufacturer: Lupin Pharma Canada Limited; listing date 2016-04-29 Health Canada: Marketed since 2016-02-29 · brand LUPIN-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 2 MG · company Lupin pharma canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lupin-Estradiol: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4083). What the ministry pays, not the patient.

Ministry pays: $0.4083 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449064)

Source record
DIN 02449064: Lupin-Estradiol Raw flags: sec3=Y Item: 681600037; group id 733; item number 1799; lccId None; manufacturer id LUP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.4083; ministry $0.4083 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449064 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93488
Interchangeable products
Estrace · DIN 02148595 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (G03CA): coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, limited Use 398
  • B + estradiol (Vagifem 10): general benefit
  • Estradiol hemihydrate (Imvexxy): general benefit
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE Some products covered without a code (check the product listing): CONJUGATED ESTROGENS 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr

ESTRADIOL 17-B

· 1 products · General benefit · strengths: 10mcg · Vag Tab with Applicator

ESTRADIOL HEMIHYDRATE

· 2 products · General benefit · strengths: 4mcg, 10mcg · Vag Insert

ESTRADIOL HEMIHYDRATE & PROGESTERONE

· 1 products · General benefit · strengths: 1mg & 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ESTRING (17 β-estradiol) is indicated for postmenopausal urogenital complaints due to estrogen deficiency such as feeling of dryness in the vagina (atrophic vaginitis) with or without pruritus vulvae, dyspareunia, dysuria and urinary urgency (atrophic mucosa in the urethra and trigonum). ESTRING should be prescribed with an appropriate dosage of a progestin for women with intact uteri, in order to prevent endometrial hyperplasia/carcinoma. The maximum recommended duration of continuous therapy is 2 years. 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): There have not been sufficient numbers of geriatric patients involved in studies utilizing ESTRING to determine whether those over 65 years of age differ from younger subjects in their response to ESTRING (See 7 Warnings and Precautions: Special Populations: Geriatrics). https://pdf.hres.ca/dpd_pm/00083118.PDF PM date: 2026-01-08 Source product: ESTRING; DIN 02168898; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.